Key result
Levosimendan improves myocardial contractility without increasing oxygen requirements and has extensive documentation supporting its safety and efficacy in acute heart failure syndromes.
Why the study?
Does levosimendan improve clinical outcomes in patients with acute heart failure, shock, or undergoing cardiac surgery?
Does levosimendan improve clinical outcomes in patients with acute heart failure, shock, or undergoing cardiac surgery?
Levosimendan is a versatile inodilator with a broad evidence base supporting its use across various acute cardiovascular settings, including heart failure, shock, and peri-operative cardiac surgery.
No takes yet. Share an insight, caveat, or question.
May support levosimendan across acute HF, shock, and peri-operative settings; leaves open outcome confirmation in prospective trials.
Luca et al. (2006) conducted a review in Acute heart failure syndromes, ischaemic heart disease, cardiogenic or septic shock. Levosimendan was evaluated. Levosimendan improves myocardial contractility without increasing oxygen requirements and has extensive documentation supporting its safety and efficacy in acute heart failure syndromes.